AcelRx CEO Richard King steps down

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) and we will feature it here at the end of each week.

AcelRx CEO Richard King steps down

Redwood City, CA-based AcelRx ($ACRX) says its CEO, Richard King, is leaving the company. He will stay on until a successor is found. This past July, AcelRx's stock plunged after the FDA rejected its application for Zalviso, a sufentanil sublingual microtablet drug/device system for fighting pain. It was a setback the company has been looking to reverse as it works with the regulators to resubmit its application at the end of this year. Release

AcelRx
Richard King will step down from the CEO position.


Actavis
R. Todd Joyce plans to retire in early 2015.

Pharma

Actavis ($ACT) CFO R. Todd Joyce will retire early next year but will stay in his post until the company finds his replacement. Release

Fred Ramsdell joined aTyr Pharma as the company's vice president of immunology. Release

Reckitt Benckiser appointed Cary Claiborne to be its chief financial officer. Release

> Horizon Pharma ($HZNP) has appointed John Kody as its chief commercial officer and executive vice president. Release

Biotech

Human Longevity appointed Barry Merriman and Paul Mola to lead its new global solutions initiative. Release

Relypsa ($RLYP) named Scott Garland its senior vice president and chief commercial officer. Release

Kurt Brykman joined Medpace as the company's COO of CRO operations, and Jesse Geiger came on as the COO of laboratory operations and CFO. Release

Chimerix ($CMRX) brought on Peter Payne as its senior vice president of business development and corporate strategy and Roberto Guzman as vice president of corporate compliance. Release

NeuroPhage Pharmaceuticals appointed Franz Hefti as its president and COO. Release

Neurocrine Biosciences ($NBIX) named Darin Lippoldt as its chief legal officer. Release

Relmada Therapeutics brought on Michael Becker as its senior vice president of finance and corporate development. Release

> Dr. Hagop Youssoufian joined Bind Therapeutics ($BIND) as chief medical officer. Release

Allergy Therapeutics appointed Dr. Daphne Tsitoura as its head of clinical science. Release

> Versartis ($VSAR) has appointed Keith Lui as vice president of marketing. Release

> Dr. Amy Sing has joined Bio-Path Holdings' ($BPTH) board of directors. Release

> Neurotrope ($NTRP) has appointed Dr. Warren Wasiewski as its chief medical officer and executive vice president of development. Release

> Michael Grey has joined Mirati Therapeutics' ($MRTX) board of directors. Release

Lpath ($LPTN) president and CEO Scott Pancoast has resigned. Release

Targovax has appointed Gunnar Gårdemyr as its new CEO. Release

Horizon Pharma ($HZNP) has added John Kody as executive vice president and chief commercial officer. Release

Donald Pearl has joined Ipsen Pharmaceuticals as vice president of neurology. Release

Cubist Pharmaceuticals ($CBST) has promoted Dr. Patrick Vink, senior vice president and general manager of Cubist's International Business, to executive vice president and chief operating officer. Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.